Syndesi Therapeutics
Chemin Du Cyclotron 6
1348 Ottignies-Louvain-La-Neuve
BE
Syndesi Therapeutics
Foundation date
19/12/2017
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera
Friday February 3rd 2023
Read more
-
Weber joins Vivactis Group to reinforce its Market Access capabilities
Thursday February 2nd 2023
Read more
-
Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health
Thursday February 2nd 2023
Read more
Jobs
More jobs-
-
02/02/23
Flemish Brabant
Research associate to support the Single Cell & Microfluidics Expertise unit
Permanent
VIB -